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EMCDDA–Europol Joint Report on a new 
psychoactive substance: methyl 
2-[[1-(cyclohexylmethyl)indole-3-carbonyl]amino]-
3,3-dimethylbutanoate (MDMB-CHMICA)
In accordance with Article 5 of Council Decision 2005/387/JHA 
on the information exchange, risk assessment and control of 
new psychoactive substances
About this series
EMCDDA–Europol Joint Report publications examine the detailed information 
provided by the EU Member States on individual new psychoactive substances. 
Information is collected from the Reitox network, the Europol national units and the 
national competent authorities of the European Medicines Agency.
Each Joint Report serves as the basis upon which the decision to conduct a risk 
assessment of the new psychoactive substance is taken. It is part of the three-step 
procedure involving information exchange, risk assessment and decision-making in the 
framework of Council Decision 2005/387/JHA.
JOINT REPORTS
MDMB-CHMICA
EMCDDA–Europol 
joint publication
2 / 20
I Acknowledgements
The EMCDDA would like to thank the following for their contribution in producing this publication:
I  the Early Warning System (EWS) correspondents of the Reitox national focal points (NFPs) and experts from their national  
EWS networks;
I  the Europol national units (ENUs) and Europol Project Synergy; 
I  the national competent authorities responsible for human and veterinary medicinal products in the Member States, Norway and Iceland; 
I  the European Medicines Agency (EMA) and the European Commission; 
I  the World Health Organization;
I  Prof. Dr. Volker Auwärter and Dr. Bjoern Moosmann, Institute of Forensic Medicine, Forensic Toxicology, Medical Center –  
University of Freiburg, Germany;
I  István Ujváry, hon. associate professor, Budapest University of Technology and Economics; hon. associate professor,  
University of Szeged; iKem BT, Budapest, Hungary.
Project team: Rita Jorge, Rachel Christie, Anabela Almeida, Michael Evans-Brown, Ana Gallegos,  
Roumen Sedefov (EMCDDA) and Daniel Dudek (Europol).
 I Contents
 3 I 1. Introduction
 3 I 2. Information collection process
 4 I 3. Information required by Article 5.2 of the Council Decision
 4 I  3.1. Chemical and physical description, including the names under which the new psychoactive substance is known  
(Article 5.2(a) of the Council Decision)
 6 I  3.2.  Information on the frequency, circumstances and/or quantities in which a new psychoactive substance is encountered, 
and information on the means and methods of manufacture of the new psychoactive substance (Article 5.2(b)  
of the Council Decision)
 6 I  3.2.1. Information provided to Europol
 8 I  3.2.2. Information provided to the EMCDDA
 9 I  3.3.  Information on the involvement of organised crime in the manufacture or trafficking of the new psychoactive substance 
(Article 5.2(c) of the Council Decision)
 10 I  3.4.  A first indication of the risks associated with the new psychoactive substance, including the health and social risks,  
and of the characteristics of users — Article 5.2(d) of the Council Decision 
 10 I  3.4.1. Serious adverse events reported to the EMCDDA
 11 I  3.4.2.  Pharmacology
 13 I  3.4.3. Toxicology
 13 I  3.4.4. Characteristics of users
 14 I  3.5.  Information on whether or not the new substance is currently under assessment, or has been under assessment, by 
the UN system (Article 5.2(e) of the Council Decision)
 15 I  3.6.  The date of notification on the Reporting Form of the new psychoactive substance to the EMCDDA or to Europol  
(Article 5.2(f) of the Council Decision)
 15 I  3.7.  Information on whether or not the new psychoactive substance is already subject to control measures at national level in a 
Member State (Article 5.2(g) of the Council Decision)
 16 I  3.8.  Further information (Article 5.2(h) of the Council Decision)
 16 I  3.8.1. The chemical precursors that are known to have been used for the manufacture of the substance
 16 I  3.8.2. The mode and scope of the established or expected use of the new substance
 16 I  3.8.3.  Other use of the new psychoactive substance and the extent of such use, the risks associated with this use of the new 
psychoactive substance, including the health and social risks
 16 I 4. Information from the EMA (Article 5.3 of the Council Decision)
 16 I  4.1. Marketing authorization
 17 I  4.2. Application for a marketing authorization
 17 I  4.3. Suspended marketing authorization
 17 I 5. Conclusion
 18 I 6. References
3 / 20
I 1. Introduction
Article 5.1 of Council Decision 2005/387/JHA (1) (hereinafter 
the ‘Council Decision’) stipulates that ‘Where Europol and the 
EMCDDA, or the Council, acting by a majority of its members, 
consider that the information provided by the Member State 
on a new psychoactive substance merits the collection of 
further information, this information shall be collated and 
presented by Europol and the EMCDDA in the form of a Joint 
Report.’ The Joint Report shall be submitted to the Council of 
the European Union, the European Medicines Agency (EMA), 
and the European Commission.
In February 2016, the EMCDDA and Europol examined the 
available information on the new psychoactive substance 
methyl 2-[[1-(cyclohexylmethyl)indole-3-carbonyl]amino]-3,3-
dimethylbutanoate, commonly known as MDMB-CHMICA, 
through a joint assessment based upon the following criteria:
1. the amount of the material seized;
2. evidence of organised crime involvement;
3. evidence of international trafficking;
4. analogy with better-studied compounds;
5. evidence of the potential for further (rapid) spread; and,
6. evidence of cases of serious intoxication or fatalities.
The EMCDDA and Europol agreed that the information collected 
on MDMB-CHMICA satisfied criteria 1, 3, 4, 5, 6. The two agencies 
therefore concluded that sufficient information had been 
accumulated to merit the production of a Joint Report on MDMB-
CHMICA as stipulated by Article 5.1 of the Council Decision.
I 2. Information collection process
In compliance with the provisions of the Council Decision, on 8 
February 2016 the EMCDDA and Europol launched a procedure for 
the collection of information on MDMB-CHMICA, in order to prepare 
the Joint Report. The information was collected mainly through the 
Reitox National Focal Points in the Member States, Turkey and 
Norway as well as the Europol National Units. In addition, the EMA 
collected information through the national competent authorities 
responsible for human and veterinary medicinal products in the 
Member States as well as in Norway, Iceland and Liechtenstein. The 
EMA also provided information as relevant to the centralised 
procedure for authorising medicinal products. 
The information collection process was largely concluded by 
21 March 2016; additional information and clarifications from 
some countries were received up to two weeks after this date.
(1) OJ L 127, 20.5.2005, p. 32.
Information collected by Europol
Europol asked the Europol National Units to provide 
information on:
QQ the level of production of MDMB-CHMICA in their country;
QQ the level of distribution of MDMB-CHMICA in their country;
QQ the level of trafficking of MDMB-CHMICA in their country, 
both for internal, transit or export purposes;
QQ the number of seizures of MDMB-CHMICA in their country, 
the total amount of the seizures, country of origin, details on 
the physical forms (including photos);
QQ the role of organised crime, or criminal groups, in the 
production, distribution and trafficking of MDMB-CHMICA in 
their country; and,
QQ any known aspect of violence and/or money laundering 
relating to the production and trafficking of MDMB-CHMICA.
Europol received responses from 17 Member States (2).
Information collected by the EMA
According to Article 5.3 of the Council Decision, the EMA 
requested that the national competent authorities responsible 
for human and veterinary medicinal products in the Member 
States, Norway, Iceland, and Liechtenstein, provide 
information on whether:
QQ the new psychoactive substance MDMB-CHMICA has 
obtained a marketing authorisation;
QQ the new psychoactive substance MDMB-CHMICA is the 
subject of an application for a marketing authorisation; and,
QQ a marketing authorisation that had been granted in respect 
of the new psychoactive substance MDMB-CHMICA has 
been suspended.
Twenty-six countries provided a response to the EMA’s 
request regarding human and/or veterinary medicinal 
products (3). The EMA also provided information as relevant to 
the centralised procedure for authorising human and 
veterinary medicinal products.
Furthermore, in anticipation of Article 7.3 of the Council 
Decision in relation to the manufacturing of medicinal 
(2) Belgium, Croatia, Cyprus, Denmark, Germany, Greece, Finland, France, 
Hungary, Italy, Latvia, Lithuania, Luxembourg, Portugal, Romania, Spain, 
and Sweden.
(3) Austria, Belgium, Croatia, Czech Republic, Denmark, Estonia, Finland, Germany, 
Greece, Hungary, Iceland, Ireland, Latvia, Norway, Poland, Portugal, Slovakia, 
Slovenia, Spain, Sweden, and the United Kingdom provided a response in relation 
to human and veterinary medicinal products. Malta provided a response in 
relation to human medicinal products. France, Italy, the Netherlands, and 
Romania provided a response in relation to veterinary medicinal products.  
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products in the European Union, the EMA also requested 
information on whether the new psychoactive substance 
MDMB-CHMICA is used to manufacture a medicinal product:
QQ which has been granted a marketing authorisation;
QQ for which an application has been made for a marketing 
authorisation; and,
QQ for which a marketing authorisation has been suspended by 
a competent authority.
Twenty-four countries (4) provided a response to the EMA’s 
request in this regard. The EMA also provided information as 
relevant to the centralised procedure for authorising human 
and veterinary medicinal products.
Information collected by the EMCDDA
The EMCDDA collected information through:
1. a structured questionnaire to the Reitox National Focal 
Points. The EMCDDA received replies from 27 Member 
States (5), as well as Turkey, and Norway;
2. data previously reported to the EMCDDA and Europol 
through European Union Early Warning System, including 
EMCDDA–Europol Reporting Forms and Progress Reports 
and Final Reports; 
3. routine monitoring of open source information;
4. a specific information request to the World Health 
Organization on whether or not MDMB-CHMICA is under 
assessment by the United Nations system; and,
5. a search of open source information conducted 
specifically for the production of the Joint Report which 
included: scientific and medical literature, official reports, 
grey literature, internet drug discussion forums and related 
websites (hereafter, ‘user websites’), and, online vendors 
selling MDMB-CHMICA.
Thus, the information included in sections 3.2.1 and 3.3 of the 
Joint Report was provided by Europol, while the EMCDDA 
provided information included in sections 3.1, 3.2.2, 3.4, 3.5, 
3.6, 3.7, 3.8.1, 3.8.2 and 3.8.3 (in part) (6). The information 
included in sections 3.8.3 (in part), 4.1, 4.2 and 4.3 was 
(4) Austria, Belgium, Croatia, Czech Republic, Denmark, Estonia, Finland, 
Germany, Greece, Hungary, Iceland, Ireland, Latvia, Poland, Portugal, 
Slovenia, Spain, and Sweden provided a response in relation to human and 
veterinary medicinal products. Malta, Slovakia, and the United Kingdom 
provided a response in relation to human medicinal products. Italy, the 
Netherlands, and Romania provided a response in relation to veterinary 
medicinal products.
(5) No reply to the Joint Report Questionnaire request was received from the 
Netherlands. 
(6) Parts of the sections on chemistry, pharmacology and toxicology, 
dependence liability and abuse potential, and characteristics of users is taken 
from a technical review on MDMB-CHMICA produced under contract from 
the EMCDDA by Dr Bjoern Moosmann and Dr Volker Auwärter (contract 
CT.16.SAT.0012.1.0).
provided by the EMA. The conclusion of the Joint Report was 
prepared and agreed by the EMCDDA and Europol who are 
the two agencies responsible for the report.
I  3.  Information required by Article 5.2 of the Council Decision
The order and titles of subsections 3.1 to 3.8 and section 4, 
below, are as they appear in Article 5.2(a) to (h) and Article 
5.3(a) to (c) of the Council Decision; sections are cross-
referenced with those set down in the Council Decision.
I 
3.1.  Chemical and physical description, including the 
names under which the new psychoactive 
substance is known (Article 5.2(a) of the Council 
Decision)
Chemical description and names
MDMB-CHMICA (Figure 1) is a synthetic cannabinoid receptor 
agonist. It appears not to have been described in the scientific 
or patent literature prior to the first detection on the drug 
market in Europe in 2014. 
MDMB-CHMICA has an indole core, which is a common 
structural feature in many of the synthetic cannabinoids 
monitored by the EMCDDA such as JWH-018 (7), which is 
controlled under the United Nations Convention on 
Psychotropic Substances, 1971.
MDMB-CHMICA possesses one asymmetric carbon atom. The 
absolute configuration has not been described in the literature. 
MDMB-CHMICA was first offered online under the misleading 
semi-systematic name ‘MMB-CHMINACA’ and although most 
of the online shops continue to offer this substance under the 
name ‘MMB-CHMINACA’, which falsely implies an indazole 
core structure, this name should not be used in the scientific 
or regulatory literature (8).
The molecular structure, molecular formula, and molecular 
mass of MDMB-CHMICA are provided in Figure 1. 
(7) Systematic name: naphthalene-1-yl(1-pentyl-1H-indol-3-yl)methanone.
(8) Different naming systems exist and are utilized for applying short/code 
names to synthetic cannabinoids and therefore inconsistencies between 
such systems can lead to erroneous and misleading short names, as seen 
here with the use of MMB-CHMINACA.
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Commonly used names: MDMB-CHMICA
Systematic (IUPAC) name: methyl 2-[[1-(cyclohexylmethyl)
indole-3-carbonyl]amino]-3,3-dimethylbutanoate
Other chemical names: methyl 2-({[1-(cyclohexylmethyl)-1H-
indol-3-yl]carbonyl}amino)-3,3-dimethylbutanoate; methyl 
2-{[1-(cyclohexylmethyl)-1H-indol-3-yl]formamido}-3,3-
dimethylbutanoate; methyl N-{[1-(cyclohexylmethyl)-1H-indol-3-
yl]carbonyl}-3-methylvalinate; N-(1-methoxy-3,3-dimethyl-1-
oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indole-3-carboxamide (9)
Other names and code names: MMB-CHMINACA
Chemical Abstracts Service (CAS) registry numbers: 
1863065-84-2 (10)
The REACH registered substances database hosted by the 
European Chemicals Agency (ECHA) was searched using the 
CAS registry number listed above. The search returned no results.
(9) This systematic name has been used in the legislation from the People’s 
Republic of China which placed MDMB-CHMICA under national drug control 
legislation on 1 October 2015.
(10) A different CAS registry number of 1715016-78-6 is reported from some 
sources on the Internet as well as in the legislation from the People’s Republic 
of China which placed MDMB-CHMICA under national drug control legislation 
on 1 October 2015.
Physical description 
In its pure form MDMB-CHMICA is an odourless, white 
crystalline solid. It is soluble up to approximately 20 mg/ml in 
DMF and 5 mg/ml in DMSO (Cayman, MSDS). The substance is 
expected to be poorly soluble in water. The melting point is 
stated to be 133–134°C (Toronto Research Chemicals, MSDS). 
Chemical stability and typical reactions
Storage in solution or under non-ideal conditions (e.g. high 
humidity or elevated temperatures) can lead to hydrolysis of 
the carboxylic ester function. Ester hydrolysis was shown to 
occur during smoking by analysis of smoke condensates 
(Moosmann and Auwärter, 2016). 
Detection and analysis
The analytical profile of MDMB-CHMICA has been described 
in a publication utilising NMR, LC-HRMS, IR and UV-VIS 
detection (Langer et al., 2016). Quantification of MDMB-
CHMICA in products can be carried out according to the 
general procedure described in the UNODC manual 
‘Recommended methods for the identification and analysis of 
synthetic cannabinoid receptor agonists in seized materials’, 
e.g. by HPLC-DAD analysis (UNODC, 2013).
FIGURE 1.
Molecular structure, molecular formula, and molecular mass of MDMB-CHMICA. Information on JWH-018 is provided  
for comparison
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I
 3.2.  Information on the frequency, circumstances 
and/or quantities in which a new psychoactive 
substance is encountered, and information on 
the means and methods of manufacture of the 
new psychoactive substance (Article 5.2(b) of 
the Council Decision)
The data reported to Europol discussed in section 3.2.1 may 
overlap with the data reported to the EMCDDA discussed in 
section 3.2.2. and 3.4.
3.2.1. Information provided to Europol
Europol received replies from 17 Member States (Belgium, 
Croatia, Cyprus, Denmark, Finland, France, Germany, Greece, 
Hungary, Italy, Latvia, Lithuania, Luxembourg, Portugal, 
Romania, Spain, and Sweden). 
The majority of countries who provided information to Europol 
reported that the information they had on MDMB-CHMICA 
was very limited. Belgium, Croatia, Italy and Portugal reported 
that they had no information on MDMB-CHMICA.
Four Member States (Germany, Hungary, Romania, and 
Sweden) provided more detailed information in relation to the 
distribution, trafficking and illicit production/processing aspects.
The level of production
Hungary and Romania indicated that criminal syndicates 
operating in their countries are responsible for tableting and/
or processing sites (mixing, packaging), where NPS imported 
from China are prepared for a final distribution (via the 
Internet and/or shipping companies).
Germany provided details on an investigation that led to the 
dismantling of a processing site, where herbal mixtures with 
MDMB-CHMICA were prepared. Tablets mimicking ecstasy 
but containing different NPS were also detected. In November 
2015 German police seized a total quantity of 17.7 kilogram of 
NPS herbal mixtures during a house search. Moreover, several 
small plastic bags contained different powders and tablets 
were found and seized and all the necessary ingredients 
required for tableting were found: caffeine, other binding 
agents, coloured substances, vitamin preparations and 
packaging units. It was stated from an individual involved in 
the processing that he mixed the herbal material with the 
synthetic cannabinoid “MMB-CHMINACA” (MDMB-CHMICA) 
and then sold the mixtures via the internet.
Forensic analysis conducted as part of this investigation 
resulted in the following findings, specifically in relation to 
MDMB-CHMICA (11):
QQ 365.62 gram of herbal mixture: MDMB-CHMICA 
QQ 9 612 gram of herbal mixture: MDMB-CHMICA and ADB-
CHMINACA.
The level of distribution 
In excess of 2100 small and bulk (12) seizure amounts were 
reported to Europol: Cyprus (6 seizures), Denmark (2), Finland 
(10), France (2), Germany (over 100), Greece (2), Hungary 
(1257), Spain (1), Latvia (2), Lithuania (46), Luxembourg (2), 
Romania (409) and Sweden (334).
Cyprus
Cyprus recorded 6 seizures of MDMB-CHMICA in 2015. In 
total 58 g of herbal material (green colour) containing MDMB-
CHMICA was seized.
Denmark
Denmark reported that 2 seizures of MDMB-CHMICA have 
taken place since December 2014. Both were seizures of plant 
material (3.1 g and 52.7 g) (SPICE) sprayed with MDMB-
CHMICA. Danish authorities stated that substance was 
purchased via the Internet (non-Danish websites) and then 
shipped to Denmark by mail.
Finland
Finland reported 10 seizures of MDMB-CHMICA were 
recorded in 2015, mostly as postal deliveries at Helsinki 
airport. In total approximately 50 g of MDMB-CHMICA was 
seized.
France
France reported 2 minor seizures of MDMB-CHMICA in 2015 
conducted by French Customs. Both seizures were post 
parcels, the first contained less than 1 g of MDMB-CHMICA 
mixed with 5F-AKB48 and the second 12 g. No seizures were 
made in 2014.
Germany
Germany brought attention to an important issue, which could 
have an effect on the total number of MDMB-CHMICA 
seizures reported. In late 2014, early 2015 it was considered 
that MDMB-CHMICA and MMB-CHMINACA were the same 
substances. Afterwards it was clarified that they are not. In 
general it is assumed that all seizures or information received 
in relation to the MMB-CHMINACA are rather MDMB-CHMICA 
(11) Other NPS were also detected as part of this investigation into a processing 
site in Germany, including: synthetic cathinones i.e. 4-CMC, buphedrone; 
arylalkylamines i.e. EAPB; and other synthetic cannabinoids i.e. ADB-
CHMINACA.
(12) In this context, ‘bulk seizure’ is defined as a single seizure in excess of 1 kg. 
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and in these cases MDMB-CHMICA was labelled as MMB-
CHMINACA just by mistake. 
According to German authorities approximately hundreds of 
seizure cases associated with MDMB-CHMICA have been 
recorded. In the majority of these cases MDMB-CHMICA was 
seized in small quantities from 0.1 g to 3.8 g. MDMB-CHMICA 
was seized both as an ingredient in so called herbal mixtures 
and also as pure substance. 
Germany provided more specific details on seizures related 
MDMB-CHMICA: 
1. Seizure of 682.41 g of herbal mixture labelled as ‘Damiana 
1kg herbal accelerator’ in March 2015. Forensic analysis 
revealed the following composition: AB-CHMINACA, 
5F-NPB-22, and MDMB-CHMICA. 
2. Seizure of 975 g of herbal mixture accompanied by a 
seizure of 3 429 g in different packages of herbal mixtures 
(from 1g to 5 g) on 7 December 2015. Results of the 
forensic analysis confirmed that MDMB-CHMICA was the 
only active substance.
3. Seizure of a total of 9 612 g of herbal mixtures with MDMB-
CHMICA and ADB-CHMINACA and 365.62 g of herbal 
mixture with MDMB-CHMICA in November 2015 (13).
Germany reported that cases associated with MDMB-
CHMICA show that this NPS is well known among drug users 
and is quite often offered either by drug dealers or via internet. 
In addition to 9 deaths associated with MDMB-CHMICA, 
German authorities recorded 34 non-fatal intoxications cases 
involving 43 persons. These incidents occurred between 
September 2014 and October 2015. The persons concerned 
were between 13 to 39 years old, most between 16 to 31 
years. 32 of them had to be hospitalized. In 22 cases the 
persons concerned had smoked a herbal mixture (e.g. Manga 
Hot, Cloud Nine, Mad Hatter, Bubblegum). Five of them 
consumed MDMB-CHMICA as a powder. In the other cases 
there is no data available concerning the consumption. 
The users suffered from nausea, dyspnoea, and tachycardia, 
inability to move and syncope as well as psychological 
problems such as disorientation, confusion, acute psychoses, 
hallucinations and delusions. In 4 cases the users were 
reported to have been in a critical condition. 
In addition, in January 2016 a traffic accident occurred in 
Seelze. The accident perpetrator (26 years old, male) could not 
remember what was happening. His pronunciation was 
unclear and highly slowed. Inside his bag an open package of 
the herbal mixture “Mr. Nice Guy Second Generation” was 
(13) This seizure information is the same as that reported in the German 
processing site detected in 2015 – see section on ‘The level of production’.
found and seized. The forensic analyses of the remainder of 
the mixture resulted 5F-ADB. The blood analyses identified 
five synthetic cannabinoids: AB-CHMINACA, AB-FUBINACA, 
5F-PB-22, MDMB-CHMICA, and ADB-CHMINACA. 
Furthermore, German police received information from a 
German jail that numerous prisoners (that were drug users) 
had collapsed, vomited, had muscle spasms and required 
hospitalisation. Checks confirmed that the prisoners received 
inconspicuous letters with normal writing paper laced with 
synthetic cannabinoids. The prisoners cut the writing paper 
into pieces and smoked them mixed with tobacco. One unit of 
consumption is about a 2x2 cm piece of paper. The forensic 
analyses identified presence of the following the synthetic 
cannabinoids: MDMB-CHMICA, AB-CHMINACA, ADB-
CHMINACA, AM-2201, AB-FUBINACA and ADB-FUBINACA.
Greece
Greece reported 2 seizures of MDMB-CHMICA. In the first case 
0.6 g herbal mixture containing MDMB-CHMICA was seized by 
the Security Department of Drapetsona. In a second case the 
Security Department of Libadeia seized 56 small plastic 
packages that contained herbal mixture with MDMB-CHMICA. 
A possible country of origin was indicated as Albania.
Hungary
Hungary formally reported the first seizure of MDMB-CHMICA 
via the EU EWS on 12 September 2014. The notification was 
based on the detection of MDMB-CHMICA in a green/brown 
herbal product of 0.19g seized by Hungarian Police in Ács in 
August 2014. 
The presence of MDMB-CHMICA was confirmed in 715 
seizures recorded in 2014 and in 542 in 2015. There have 
been 19 seizure of the substance in the powder form with 
total amount of 225 g and 1178 seizures of herbal material 
with total amount of 5.01 kg. In 31 % of all reported seizures 
the substance was mixed with other compounds. The other 
NPSs frequently mixed together with MDMB-CHMICA were, 
for instance 5F-AMBICA (10 % of the seizures), 5F-AMB (5 % 
of the seizures) and AB-CHMINACA (4 % of the seizures). The 
purity of powder samples in 5 cases analysed by forensic 
analysis revealed very high concentrations of 95 % or more. 
The concentration of the MDMB-CHMICA in herbal mixture 
was identified at being from 1 to 8 %.
In the majority of cases the MDMB-CHMICA was sent from 
China and, to a lesser extent, the United Kingdom. Air cargo 
shipments or mail orders were often used through Budapest 
Ferenc Liszt International Airport. In the course of 
investigation an important link was identified with a company 
based in the United Kingdom that provided different NPS, 
including MDMB-CHMICA to Hungary.
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Latvia
Latvia reported 1 postal seizure recorded in 2015. The parcel 
arrived from the United Kingdom. In total 6.0814 g of herbal 
mixture was seized containing MDMB-CHMICA and 
5F-AKB48. In another case Latvian authorities seized 
115.6262 g MDMB-CHMICA as herbal mixture.
Lithuania
Lithuanian authorities recorded 46 seizures of MDMB-
CHMICA in 2015, with a total amount of 4 kg 405 g. The 
largest single seizure was 4 kg, with purity of 0.2 %.
Luxembourg
In Luxemburg there have also been two seizures recorded in 
2014 and 2015 one of which is the biggest single seizure of 
this substance reported in the EU. The biggest seizure was 
reported in 2014 and was seized in freight cargo from China 
(Shanghai) and was destined for Spain (Madrid). In total 40 kg 
of MDMB-CHMICA in powder form was seized.
The second minor seizure was recorded in 2015, when during 
a music festival 1.2 g of herbal mixture with traces of MDMB-
CHMICA was seized (country of origin is unknown).
Romania
Romania reported this substance via the EWS to the EMCDDA 
in November 2014 for the first time. In 2015 409 seizures of 
MDMB – CHMICA have been registered, with a total amount 
of 9 423.005 grams. Intelligence revealed that in the majority 
of cases the substance was imported from China. In one 
particular case investigated by the Romanian authorities, a 
criminal group imported NPS from China to Romania via the 
Czech Republic and Hungary.
Members of this criminal organisation were Hungarian 
nationals with Croatian origin. 
Romanian authorities also underlined significant problems 
with the identification of this particular NPS in all overdose/ 
hospitalised cases in Romania, due to the lack of a proper 
identification tool. Therefore, no links have been found 
between MDMB-CHMICA as a contributing compound to 
registered overdoses cases in Romania.
As it was stated the substance was imported from China via 
internet and then distributed via different countries. During 
investigations two websites were identified as facilitators to 
order this NPS.
Spain
Spain reported 1 seizure of MDMB-CHMICA in 2015, in the 
framework of a law enforcement operation. In total 4.8 kg of 
the substance were seized and four persons (Italian citizens) 
were arrested. It was reported that Spain was not a final 
destination for this shipment, but other unspecified Member 
States.
Sweden
Sweden reported the following seizure data recorded by 
Swedish law enforcement agencies:
QQ 173 seizures in 2014 (154 seizures were analysed in 2014)
QQ 159 seizures in 2015 (187 seizures were analysed in 2015)
QQ 2 seizures in 2016 (4 seizures were analysed in 2016).
The total amount of this seizures was 1 637 gram analysed in 
2014, 1 740 gram analysed in 2015 and 192 gram analysed in 
2016. The total amount of seizures from January 2014 until 
beginning of February of 2016 was 3 570 grams.
In addition, Sweden reported that MDMB-CHMICA has been 
sold on the internet. As for spice in general, the spread of this 
substance has been seen all over the country with some 
concentration to certain parts, mostly smaller cities. There 
have also been a few cases recorded in Stockholm. After 
scheduling of this substance there have been no internet 
sales at Swedish marketplace. The most common users 
identified for this substance are men born in the 1990’s.
3.2.2. Information provided to the EMCDDA
The EMCDDA received responses from 27 Member States, as 
well as from Turkey and Norway. Of these, 19 Member States 
(Austria, Belgium, Bulgaria, Croatia, Denmark, Estonia, 
Finland, France, Germany, Greece, Hungary, Latvia, Lithuania, 
Luxembourg, Poland, Romania, Sweden, Slovakia and the 
United Kingdom), Turkey, and Norway reported detections of 
MDMB-CHMICA (14).
Seizures
Overall, in excess of 3 600 seizures (15) were reported to the 
EMCDDA by 19 Member States, Turkey, and Norway: Austria 
(20 seizures), Belgium (2), Bulgaria (16), Croatia (33), 
Denmark (4), Estonia (15), Finland (53), France (5), Germany 
(1), Greece (3), Hungary (1405), Latvia (10), Lithuania (52), 
Luxembourg (2), Poland (223), Romania (2), Sweden (521), 
(14) ‘Detections’ is an all-encompassing term and may include seizures and/or 
collected and/or biological samples that are analytically confirmed. Seizure 
means a substance available (seized) through law enforcement activities 
(police, customs, border guards, etc.). Collected samples are those that are 
actively collected by drug monitoring systems (such as test purchases) for 
monitoring and research purposes. Biological samples are those from human 
body fluids (urine, blood, etc.) and/or specimens (tissues, hair, etc.) 
(15) Many ‘seizures’ relate to individual case-level data, however, some data provided 
to the EMCDDA are aggregated at the country level. Data is drawn from the Joint 
Report Questionnaires and data provided in the bi-annual data gathering (EU 
EWS Progress Reports and Final Reports) and from individual EMCDDA–
Europol Reporting forms submitted to the EMCDDA on an ad hoc basis.
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Slovakia (3), the United Kingdom (550), Turkey (656), and 
Norway (9).
MDMB-CHMICA has typically been seized as herbal material. 
Over 90 % of seizures reported by countries where MDMB-
CHMICA has been detected have been of herbal material. This 
includes the seizure of a large number of branded ‘legal high’ 
smoking mixtures. Over 98 kg of MDMB-CHMICA has been 
seized, almost 54 kg of which was seized as herbal material 
and almost 43 kg seized in powder form. In the remaining 
amount seized, the physical form of MDMB-CHMICA was 
undefined. 
The largest single bulk seizure reported to the EMCDDA was 
40 kg of MDMB-CHMICA in powder form by Luxembourg, in 
December of 2014. The powder was contained in 1 kg 
packages and was seized at Luxembourg airport where it was 
in transit from China (Shanghai) with Spain (Madrid) as the 
final destination.
Seizures in excess of 1 kg were reported by 7 countries: 
Hungary (6.8 kg), Latvia (1.2 kg), Luxembourg (40 kg), 
Romania (2.9 kg), Sweden (4.9 kg), Turkey (34.8 kg) and the 
United Kingdom (5.9 kg).
Where MDMB-CHMICA has been detected with other 
substances, it has almost exclusively been detected in 
combination with other synthetic cannabinoids such as: 
5F-AMB (5F-AMB-PINACA), 5F-AMBICA, AB-CHMINACA, 
5F-AKB48, 5F-AMB-PINACA, and AB-FUBINACA.
Collected samples
A total of 4 Member States reported 60 samples that 
contained MDMB-CHMICA collected from users and from 
bricks-and-mortar shops and online shops: Spain (3), France 
(2), Slovenia (2), and the United Kingdom (53). Some of these 
collected samples were linked to biological detections 
including serious adverse events.
The first collected sample was reported by the United Kingdom 
in September 2014 and was a sample mislabelled as MMB-
CHMINACA. The most recently reported collected sample was 
also reported by the United Kingdom in February 2016.
Biological samples
A total of 306 detections where MDMB-CHMICA was 
analytically confirmed in biological samples were reported by 
7 Member States (Austria, Germany, Estonia, Hungary, Poland, 
Sweden and the United Kingdom) and Norway. 
These related to:
QQ 53 serious adverse events (25 acute intoxications and 
28 deaths);
QQ 10 cases related to intoxications reported to the Poisons 
Information Centre (aggregated data, details not specified);
QQ 135 cases reported as aggregated data associated with 
forensic case work (details not specified); 
QQ 8 cases of persons suspected of driving under the influence 
of drugs (including 1 traffic accident);
QQ 100 cases related to unlawful activity (which included 
driving under influence of drugs/alcohol, underage drinking, 
violent public behaviour, or suspicion of drug consumption).
I 3.3.  Information on the involvement of organised crime in the manufacture or trafficking of the new psychoactive substance (Article 5.2(c) of the Council Decision)
No detailed information concerning the involvement of 
organised crime in the manufacture and/or trafficking of 
MDMB-CHMICA was provided by any of reporting states. 
The level of trafficking
No detailed information concerning the involvement of 
organised crime in the manufacture and/or trafficking of 
MDMB-CHMICA was provided by any of reporting states.
However, 3 Member States (Germany, Hungary, and Romania) 
referred to an involvement of the criminal groups in whole 
chain of the NPS trade (from importation to final distribution).
German authorities stated that no direct links with organised 
crime groups (OCG) have been identified. However, easy 
access to the MDMB-CHMICA in smaller amounts via Internet-
shops in and outside of the EU, as well as in bigger amounts 
via Internet trade boards mostly from wholesalers in China or 
other Asian countries indicate at least a certain degree of 
organisation.
Hungary and Romania highlighted that criminal syndicates 
that operate in their countries are responsible for setting up 
tableting and/or processing sites (mixing, packaging), where 
NPS imported from China are prepared for final distribution 
(via Internet and/or shipping companies).
Money laundering aspects
No specific information was received on money laundering 
phenomenon, in relation to the production and/or trafficking of 
MDMB-CHMICA. 
Romania however reported the incomes generated by criminal 
groups that deal with NPS are used to purchase real estates 
and vehicles. During a few investigations conducted by the 
Romanian authorities those types of goods purchased by 
criminal syndicates for money derived from criminal activities 
were identified and seized.
JOINT REPORTS I MDMB-CHMICA
10 / 20
Violence in connection with production, wholesale and 
distribution
No information was reported in respect to violence in 
connection with production, wholesale and distribution of 
MDMB-CHMICA.
I 3.4.  A first indication of the risks associated with the new psychoactive substance, including the health and social risks, and of the characteristics of users — Article 5.2(d) of the Council Decision 
3.4.1. Serious adverse events reported to the EMCDDA
Case-level data for 71 serious adverse events (16) associated 
with MDMB-CHMICA were reported to the EMCDDA by 8 
Member States (Austria, France, Germany, Hungary, Poland, 
Spain, Sweden, and the United Kingdom) and Norway. These 
cases comprised 42 acute intoxications and 29 deaths; they 
occurred between 2014 and 2016 (17). 
Acute intoxications
Case-level data for 42 acute intoxications associated with 
MDMB-CHMICA were reported by 7 countries: Austria (7 
cases), France (2), Germany (7), Poland (3), Spain (2), Sweden 
(10) and the United Kingdom (11). 
For 35 of these cases, analytical confirmation of consumption 
of MDMB-CHMICA was obtained from biological samples (25 
cases) or from epidemiologically linked samples (products 
either used or presumed to have been used by the patients) 
(10 cases). The remaining 7 cases (3 cases from Poland and 
4 cases from Sweden) were excluded from further analysis 
because MDMB-CHMICA was not analytically confirmed from 
either a biological sample or an epidemiologically linked 
sample.
(16) Serious adverse event means any adverse event, whether analytically 
confirmed or not, that is associated with the consumption of a new 
psychoactive substance in a human that: results in death; is life-
threatening; requires intensive treatment in an emergency room and/or 
requires hospitalisation; results in persistent or significant disability or 
incapacity; results in substance dependency or substance abuse; consists of 
a congenital anomaly or birth defect; or is an important medical event that 
may not be immediately life-threatening or result in death or hospitalisation 
but may jeopardise the patient or may require intervention to prevent one of 
the other outcomes listed above. Examples of such events are: convulsions 
that do not result in hospitalisation.
(17) Europol received reports of 34 acute intoxications and 9 deaths associated 
with MDMB-CHMICA occurring in Germany between September 2014 and 
October 2015. Some of these reports may be duplicates with the data 
reported to the EMCDDA. However, given the strict deadlines imposed by the 
Council Decision 2005/387/JHA it had not been possible to ascertain this at 
the time of writing the Joint Report. As a result, the analysis below refers to 
the 71 serious adverse events reported to the EMCDDA.
The large majority of 35 cases appear to have been treated in 
hospital emergency departments. All the cases occurred 
during 2014 and 2015. In 19 out of 35 cases the individuals 
recovered; for the remaining 16 cases the outcome of the 
intoxication was unknown or not reported.
In 3 of the 25 acute intoxications that were analytically 
confirmed from biological samples, MDMB-CHMICA was the 
only substance identified. In the remaining 22 cases MDMB-
CHMICA was detected along with other substances. These 
were typically other cannabinoids (including THC and its 
metabolites) and ethanol. Other substances detected 
included benzodiazepines, morphine, and buprenorphine.
Demographics
26 (74 %) of the acute intoxications were male; 7 (20 %) were 
female; in 2 (6 %) cases the gender of the patient was unknown. 
The mean age of the male cases for which an age was known 
was 25 years (median 22); for the female cases for which an 
age was known, the mean age was 27 years (median 20). For all 
cases, the ages ranged between 15 and 50 years old.
Clinical symptoms 
Data on the clinical symptoms (18) related to the 3 intoxications 
where MDMB-CHMICA was the only substance detected were 
generally consistent with those associated with intoxication by 
synthetic cannabinoids previously reported in the literature 
(Tait et al., 2016). These included: confusion, aggression, 
changes in mood, hallucinations, dilated pupils, hyperemesis, 
and unresponsiveness.
For the remaining 32 cases, the reported symptoms were also 
generally consistent with the symptoms associated with 
intoxication by synthetic cannabinoids (Tait et al., 2016). These 
included: unconsciousness or coma (12 cases), hyperemesis 
and/or nausea (6), seizures and convulsions (5), tachycardia 
(5), bradycardia (2), mydriasis (3), syncope (2), spontaneous 
urinating and defecating (2), shortness of breath (2), 
somnolence (2), respiratory acidosis (1) metabolic acidosis (1), 
collapse (1), lower limbs paralysis (1), and chest pain (1).
Aggression and/or severe disturbance of behaviour were 
reported in at least 6 cases, some of which resulted in police 
intervention and transfers to psychiatric units.
(18) Includes abnormal laboratory findings. 
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Route of administration
In 21 cases the route of administration was reported to be 
smoking or inhalation. 
Physical form
In 18 cases the physical form of MDMB-CHMICA used by the 
patients was reported to be herbal material. In two cases the 
herbal material containing MDMB-CHMICA was mixed with 
another synthetic cannabinoid as a powder.
Amount or dose administered
No information was reported on the amount of MDMB-
CHMICA used by the patients. In one case the serious adverse 
effects were felt after smoking ‘1 joint’; in another the patient 
felt the adverse effects after ‘2 or 3 inhalations’.
Deaths
Case-level data for 29 deaths associated with MDMB-
CHMICA were reported by 5 Member States and Norway: 
Germany (5 cases), Hungary (3), Poland (1), Sweden (9), the 
United Kingdom (10), and Norway (1). MDMB-CHMICA was 
analytically confirmed in biological samples in 28 cases and 
from an epidemiologically linked sample in 1 case.
Demographics
Of the 29 deaths, 25 were male (86 %), 3 were female (10 %), 
the gender was not reported for one death (19). The decedents’ 
ages ranged from 17 to 52 years old. The mean age of the 
male decedents was 33 years (median 33); the mean age of 
the female decedents was 31 years (median 30).
Cause of death
The cause of death was reported in 21 cases. For the 
remaining 8 cases information on the cause of death was not 
available.
QQ In 1 case the cause of death was reported to be caused by 
MDMB-CHMICA;
QQ In 4 cases the information provided on the cause of death 
suggested that it was probably or possibly caused by 
MDMB-CHMICA;
QQ In 5 cases MDMB-CHMICA was reported to have contributed 
to the cause of death;
QQ In 2 cases the information provided on the cause of death 
suggested that MDMB-CHMICA probably or possibly 
contributed to the cause of death;
QQ In 2 cases the cause of death was reported as drug overdose 
or mixed intoxication;
QQ In 7 cases an alternative cause of death was reported.
(19) No gender was reported for one of the cases. 
Route of administration
In all the 11 fatalities for which a route of administration was 
reported, MDMB-CHMICA was either smoked (9 cases) or 
presumed to have been smoked (2).
Source
Information on where the decedents had sourced the 
substance was available in 3 cases: in 2 of them MDMB-
CHMICA was sourced from the internet. In the remaining case 
the substance was supplied by a friend.
Amount or dose administered
No information was reported on the amount of substance 
administered by the decedents.
3.4.2.  Pharmacology
Pharmacodynamics
MDMB-CHMICA is a highly potent full agonist at the CB
1
 
receptor of the endocannabinoid system. Using a cAMP 
assay MDMB-CHMICA showed an EC
50
 approximately 8 
times lower than the EC
50
 of JWH-018, and a twofold lower 
EC
50
 than AB-CHMINACA (20) (Table 1) (Moosmann and 
Auwärter, 2016).
The relatively high pharmacological potency is also supported 
by the data available for other synthetic cannabinoids and 
from structure-activity relationships (SAR). Frequently, a 
substitution of the indole core structure with an indazole core 
leads to a significant reduction of the activity at the CB
1
 
receptor. This was observed in the case of APICA (21) and 
APINACA (22) (IC
50
: 175 nM vs. 824 nM) (Uchiyama et al., 
2012) and in the case of AM-2201 and THJ-2201 (EC
50
: 
0.45 nM vs. 1.68 nM) (Moosmann and Auwärter, 2016). 
TABLE 1
Half maximal effective concentration (EC
50
) and efficacy as 
compared to the full agonist CP 55,940 (E
max
) of MDMB-
CHMICA and other synthetic cannabinoids as assessed using 
a cAMP assay (CB1 receptor, DiscoverX) (Moosmann and 
Auwärter, 2016)
Compound EC
50
 [nM] E
max
JWH-018 1.13 97%
MDMB-CHMICA 0.14 94%
AB-CHMINACA 0.27 94%
AB-FUBINACA 0.89 97%
(20) Systematic name: N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-
(cyclohexylmethyl)-1H-indazole-3-carboxamide.
(21) Systematic name: N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide.
(22) Systematic name: N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide.
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Comparing the binding affinity towards the CB
1
 receptor and 
the intrinsic activity of compounds carrying an isopropyl 
moiety (e.g. AB-CHMINACA) with their respective tert-butyl 
analogues (e.g. ADB-CHMINACA(23)), it can be observed that 
the introduction of a tert-butyl moiety typically leads to an 
increase in affinity and activity of the compounds (e.g. 
AB-CHMINACA K
i
: 0.519 nM; EC
50
:IC
50
 2.55 nM vs. ADB-
CHMINACA K
i
: 0.289 nM; EC
50
:IC
50
 0.62 nM) (Moosmann  
and Auwärter, 2016). 
Furthermore, comparing the CB
1
 receptor affinities and 
activities of carboxamide compounds with their methyl ester 
analogues, a significant further increase can frequently be 
observed (e.g. ADB-CHMINACA K
i
: 0.289 nM; EC
50
:IC
50
 
0.62 nM vs. MDMB-CHMINACA K
i
: 0.094 nM; EC
50
:IC
50
 
0.330 nM) (Bluchler et al., 2011; Buchler et al., 2009; Banister 
et al., 2015).
Langer and co-workers (Langer et al., 2016) report a K
i
 of 
MDMB-CHMICA at the CB
1
-receptor of 0.09 nM. However, the 
reference stated by the authors does not contain data on 
MDMB-CHMICA. Instead, the K
i
 of MDMB-CHMINACA is 
reported there with the same value. 
As it has been shown for some of the first synthetic 
cannabinoids to appear on the drug market (e.g. JWH-018, 
JWH-073) and for the THC metabolite 11-hydroxy-THC, it is 
likely that some of the mono-hydroxylated metabolites of 
MDMB-CHMICA retain activity at the CB
1
 receptor and they 
might therefore contribute to the pharmacological profile of 
the compound. However, in the case of CB
1
 receptor activity, it 
is unclear if the metabolites are able to cross the blood-brain-
barrier and reach effective concentrations levels in the central 
nervous system. Based on the properties of structurally 
related compounds like MDMB-CHMINACA or ADB-
CHMINACA, the ester cleavage product (a free carboxylic 
acid) may not show relevant affinity towards the CB
1
 receptor 
(Buchler et al., 2011).
No data regarding the binding affinity or activity towards the 
CB
2
 receptor is available in the literature. In contrast to CB
1
 
receptors, CB
2
 receptors are mainly expressed on cells of the 
immune system and consequently, if MDMB-CHMICA binds to 
the CB
2
 receptor, modulation of the immune system could be 
the result.
There are no data available on the effect of MDMB CHMICA on 
other pharmacological (receptor or enzyme) targets. The 
biological properties of its metabolites are also unknown.
(23) Systematic name: N-[1-(aminocarbonyl)-2,2-dimethylpropyl]-1-
(cyclohexylmethyl)-1H-indazole-3-carboxamide.
Pharmacokinetics
MDMB-CHMICA undergoes extensive metabolism in the 
human body. Similar to other synthetic cannabinoids which 
have been studied it is not excreted unchanged in urine to a 
relevant extent. 
The main metabolic reactions comprise mono-hydroxylations 
and hydrolysis of the carboxylic ester function. In total, 31 
metabolites could be identified in vivo (Moosmann and 
Auwärter, 2016. The four most abundant metabolites detected 
in human urine samples were products of either mono-
hydroxylation of the cyclohexyl moiety or hydrolysis of the 
carboxylic ester function.
No data on the pharmacokinetics of MDMB-CHMICA is 
available in the literature.
Abuse liability and dependence potential
Abuse liability
Limited information from self-reported user experiences on 
user websites appear to suggest that MDMB-CHMICA has an 
abuse potential.
Other synthetic cannabinoids (JWH-018, JWH-073, JWH-200, 
CP-47,497 and cannabicyclohexanol) have previously been 
found to have potential for abuse (Järbe et al., 2011; Järbe et 
al., 2010; Ginsburg et al., 2012; DEA, 2012).
Dependence potential
No data are available in the literature regarding the 
dependence potential of MDMB-CHMICA in animals. Studies 
evaluating the dependence potential of other synthetic 
cannabinoids (Ginsburg et al., 2012) suggest that JWH-018 
and JWH-073 might have some abuse and dependence 
liability in monkeys due to a short duration of action. In rhesus 
monkeys, cross-tolerance was observed after 3 days of THC 
treatment for THC but not for JWH-018 (Hruba et al., 2012). 
The greater loss of sensitivity to Δ9-THC relative to JWH-018 
suggests that differences in CB
1
 receptor agonist efficacy are 
important in vivo and might underlie differences in the 
dependence liability and adverse effects of synthetic 
cannabinoids versus cannabis.
No data are available from clinical studies on the dependence 
potential of MDMB-CHMICA. Four cases of withdrawal 
symptoms following MDMB-CHMICA consumption were 
reported to the Poison Information Centre in Freiburg, 
Germany (Moosmann and Auwärter, 2016). The duration and 
extent of consumption was not reported.
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Other synthetic cannabinoids have been previously found to 
produce withdrawal symptoms (24) in humans (Hermanns-
Claussen et al., 2013; Hermanns-Claussen et al., 2012).
3.4.3. Toxicology
No published data regarding the toxicity of MDMB-CHMICA 
have been identified.
Data on cytotoxicity and genotoxicity exists for other synthetic 
cannabinoids (Koller et al., 2013a; Koller et al., 2013b; Koller et 
al., 2015; Ferk et al., 2016) but transferability of these data to 
MDMB-CHMICA is very limited as individual compounds can 
show distinct toxicological profiles.
Data from serious adverse events associated with MDMB-
CHMICA are discussed in this section 3.4.1. Based on the data 
reported, the symptoms presented in cases of intoxication 
involving MDMB-CHMICA appear to be broadly similar to 
those found with other synthetic cannabinoids.
3.4.4. Characteristics of users
There is limited data on the characteristics of users of MDMB-
CHMICA. ‘Legal high’ smoking mixtures containing MDMB-
CHMICA are marketed as ‘legal’ replacements to cannabis. It 
is therefore likely that a range of different cannabis users 
would be interested in these products. Among other groups 
this will include those who are regularly subjected to drug 
testing procedures (see section below on Prevalence of use). 
Information provided to Europol suggests that MDMB-
CHMICA has also been consumed by prisoners.
Some of the information available on the users of MDMB-
CHMICA discussed in this section derives from self-reported 
user experiences. It is important to note that it is not possible 
to confirm the specific substance(s) used by those submitting 
the reports; nor the strength, purity and dose consumed. 
While this is generically true for user reports of all new 
psychoactive substances, it is particularly relevant for users of 
‘legal high’ type herbal mixtures containing synthetic 
cannabinoids, which are widely known to be highly variable in 
terms of composition and dosage. 
It is also important to note that the information provided on 
user websites and from specific user groups may not 
(24) Withdrawal symptoms after cessation of synthetic cannabinoid use 
described in the literature include: anxiety, unstable mood, crying fits, feeling 
of inner emptiness, spatial disorientation, hyperacusis, somatic pain, 
shortness of breath, hyperventilation, intense sweating, and sensations of 
motor and inner restlessness.
necessarily be representative of other users of MDMB-
CHMICA and should be regarded as illustrative only.
Route of administration, drug regimens and settings of use
MDMB-CHMICA is typically sold as branded ‘legal high’ 
smoking mixtures which are usually smoked or otherwise 
inhaled; use of self-prepared herbal mixtures have also 
occasionally been reported.
Herbal mixtures containing MDMB-CHMICA can be 
administered as a ‘joint’ or using a vaporizer, ‘bong’ or pipe. 
Oral consumption of synthetic cannabinoids as powders or 
tablets has also been described, albeit to a lesser extent. In 
the case of oral consumption a strong first-pass-effect can be 
expected. 
Dose, re-dosing
There are no clinical studies on the doses required to produce 
subjective effects of MDMB-CHMICA. Limited data from 
self-reported user experiences posted on user websites claim 
that subjective effects have been noted using doses of 0.05 
mg to 0.3 mg. 
It is well established that herbal smoking mixtures vary 
considerably in terms of composition and content of synthetic 
cannabinoids. In addition, heterogeneity of the distribution of 
the MDMB-CHMICA within the herbal mixture can result in 
uneven and high concentrations of the substance on certain 
parts of the herbal material (so called ‘hot pockets’) 
(Mooosmann et al., 2015). 
Overall, it is reasonable to assume that the vast majority of 
users have no idea that they are consuming MDMB-CHMICA, 
nor what dose they are taking, nor will they be able to reliably 
control the dose they consume.
Subjective, psychological, and behavioural effects
There are no non-clinical or clinical studies reporting on the 
psychological and/or behavioural effects of MDMB-CHMICA. 
Discussions on user websites suggest that the subjective 
effects might be similar to those induced by other synthetic 
cannabinoids. Reported effects are wide ranging and include 
euphoria, feeling of warmth, spontaneous laughing, visual and 
auditory hallucinations, as well as severe anxiety and fear/
panic, disorientation, vertigo and violent behaviour. 
Data from serious adverse events reported to the EMCDDA 
include reports of serious acute behavioral disturbances in 
individuals who have been exposed to MDMB-CHMICA.
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Availability, supply, price
Online vendors
A search of the product portfolio of 95 online shops selling 
research chemicals in various countries (Belgium, Czech 
Republic, Germany, Hungary, The Netherlands, Poland, Spain, 
Sweden, United Kingdom, Canada, USA, China) was 
performed. More than one third of the shops (28 shops) listed 
MDMB-CHMICA on their website, but only two named the 
compound ‘MDMB-CHMICA’ (all others named it ‘MMB-
CHMINACA’). In 6 of these 28 shops the compound was listed 
as ‘out of stock’. Online prices depended on the order quantity 
and are summarised in Table 2.
It should be noted that MDMB-CHMICA was controlled in 
China in October 2015. Despite the change in legal status, 
some online vendors claiming to be based in China still list 
MDMB-CHMICA on their webpage, although they do not ship 
the compound anymore (Moosmann and Auwärter, 2016).
Prevalence of use
No published data from general population surveys or 
targeted surveys on the prevalence of use of MDMB-CHMICA 
were identified. 
The EU ‘SPICE’ project (25) reported that in 2015, 186 samples 
of synthetic cannabinoids that were test purchased (44 % of 
all analysed ‘herbal mixtures’) contained MDMB-CHMICA 
(Moosmann and Auwärter, 2016). This appears to suggest that 
in 2015 MDMB-CHMICA was commonly found in ‘legal high’ 
smoking mixtures being sold on the market, even though the 
representatively of the samples analysed cannot be 
commented on. 
An analysis of all the serum and urine analysis conducted at 
the Institute of Forensic Medicine in Freiburg (Germany) 
(n=1,377 samples) suggests that MDMB-CHMICA was the 
(25) EU funded research project (2010–12), continued by the ‘Spice II Plus’ project 
aimed at ensuring a scientific knowledge base (including analytical libraries) 
on synthetic cannabinoids and other new psychoactive substances (http://
polis.osce.org/library/f/4276/4274/OSCE-BIH-EVT-4276-EN-4274.pdf) 
most prevalent synthetic cannabinoid in Germany in 2015. The 
substance was detected in 54 % (n=205) of all serum samples 
positive for synthetic cannabinoids (n=1,377) (Moosmann and 
Auwärter, 2016).
‘Legal high’ smoking mixtures containing MDMB-CHMICA are 
marketed as ‘legal’ replacements to cannabis. It is therefore 
likely that a range of different cannabis users would be 
interested in these products. Among others, this would 
include those subjected to regular drug testing (such as those 
tested for drug abstinence in the context of drug treatment 
centres, workplace testing, driving licence re-granting 
candidates, etc.). Avoidance of drug testing was considered to 
be a relevant motivation for the use of synthetic cannabinoids 
by a study who surveyed adults (from 13 different countries) 
reporting at least one (lifetime) use of synthetic cannabinoids 
(Vandrey et al., 2012).
Information on the use of MDMB-CHMICA can also be 
ascertained from discussions on user websites (26,27), despite 
the (already discussed) limitations of this type of data. From 
these discussions, it appears that MDMB-CHMICA is also 
used by psychonauts and users with experience of other 
synthetic cannabinoids.
I 3.5.  Information on whether or not the new substance is currently under assessment, or has been under assessment, by the UN system (Article 5.2(e) of the Council Decision)
The World Health Organization is the specialised United Nations 
agency designated for the evaluation of the medical, scientific 
and public health aspects of psychoactive substances under 
the Single Convention on Narcotic Drugs, 1961 and the 
Convention on Psychotropic Substances, 1971. On 9 February 
(26) www.erowid.org/experiences/exp.php?ID=105904 
(27) www.bluelight.org/vb/threads/735246-New-cannabinoid-MMB-
CHMINACA?highlight=MDMB-CHMICA
TABLE 2
Online prices of MDMB-CHMICA. Exchange rates used for calculation in €: 1 GBP = 1.30 €; 1 USD = 0.90 €, 1 PLN = 0.23
1 g 10 g 100 g 1000 g
Number of products 16 20 19 16
Range 8.50 – 23.40 60.00 – 203.40 405 – 770 1 620 – 6 100
Median 13.90 97.50 545 3 600
Mean 14.93 98.43 556 3 505
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2016, the World Health Organization informed the EMCDDA 
that MDMB-CHMICA is currently not under assessment and 
has not been under assessment by the UN system.
I 3.6.  The date of notification on the Reporting Form of the new psychoactive substance to the EMCDDA or to Europol (Article 5.2(f) of the Council Decision)
The first official EMCDDA–Europol notification of MDMB-
CHMICA dates from September 2014 from the Hungarian 
National Focal Point. The Reporting Form details a seizure of 
0.19 g of green/brown herbal product that was seized in 
August 2014 by Hungarian Police in Ács, Hungary. The 
identification and analytical characterisation was based on 
Gas Chromatography-Mass Spectrometry (GC-MS) and 
Fourier transform infrared spectroscopy (FT-IR) and Nuclear 
Magnetic Resonance (NMR).
MDMB-CHMICA was added to the list of new psychoactive 
substances monitored by the EMCDDA and Europol through 
the European Union Early Warning System and a profile of the 
substance was created on the European Database on New 
Drugs (EDND). Since then, analytical details and other 
information, including public health alerts, have been 
exchanged between the EMCDDA, Europol, and the Member 
States, Turkey, and Norway, on an ad hoc basis; the European 
Commission and the EMA have been kept duly informed.
I 3.7.  Information on whether or not the new psychoactive substance is already subject to control measures at national level in a Member State (Article 5.2(g) of the Council Decision)
Ten Member States (Croatia, Denmark, Estonia, Finland, 
Germany, Greece, Hungary, Latvia, Lithuania, and 
Luxembourg) and Turkey reported that MDMB-CHMICA is 
controlled under drug control legislation.
QQ In Croatia, MDMB-CHMICA is part of the list of drugs, 
psychoactive substances and plants used for drug 
production, as well as precursors (OG 10/16). MDMB-
CHMICA is covered with generic definition ‘JWH-018 and its 
structural analogues’.
QQ In Denmark, MDMB-CHMICA is controlled under drug control 
legislation.
QQ In Estonia, MDMB-CHMICA has been added to drug control 
legislation since 8 June 2015.
QQ In Finland, MDMB-CHMICA has been added to drug control 
legislation since 28 September 2015.
QQ In Germany, by adoption of the 30th Amending Regulation 
on Narcotic Drugs (30. Betäubungsmittelrechts-
Änderungsverordnung, BtMÄndV) MDMB-CHMICA is 
controlled under schedule I (narcotics not eligible for trade 
and medical prescription) of the German Narcotics Act 
(Betäubungsmittelgesetz, BtMG). The legislation has been 
published on November 11th 2015 in the Federal Gazette, 
and entered into force on 21 November 2015. 
QQ In Greece, MDMB-CHMICA is classified as an isomer of 
Zipeprol (28). Zipeprol and its isomers are classified in the 
Table C of the Law 4139/2013. 
QQ In Hungary, MDMB-CHMICA is under drug control legislation 
from 22/07/2015 through Government Decree 66/2012 (IV. 2.).
QQ In Latvia, MDMB-CHMICA is included in the first list of the 
Cabinet Regulation N 847 ‘Regulations regarding Narcotic 
Substances, Psychotropic Substances and Precursors to be 
Controlled in Latvia’ and the law ‘On the Procedures for the 
Coming into force and Application of the Criminal Law’. 
Control of MDMB-CHMICA is introduced by the generic 
approach.
QQ In Lithuania, MDMB-CHMICA has been placed under control, 
according to the Republic of Lithuania Minister of Health 
Order No V-1062 (21/09/2015) ‘On the amendment of the 
Ministry of Health of the Republic of Lithuania Order No. 5 of 
6 January 2000.
QQ In Luxembourg, MDMB-CHMICA is controlled by the Grand 
Ducale Decree of 04/05/2009.
QQ In Turkey, MDMB-CHMICA is under legal control via the 
Generic Classification which was deliberated by the council 
of Ministers on 26/01/2015 and published in the official 
gazette on 6 February 2015 the annexed list subject to the 
provisions of the Law on Control of Drugs numbered 2313; 
according to the 19th article of the said Law. Generic 
Classification text is updated and adopted to the said law on 
16/02/2016 by the council of Ministers.
Two Member States (Austria and Poland) reported that 
MDMB-CHMICA is controlled under specific new psychoactive 
substances control legislation.
QQ In Austria, MDMB-CHMICA is controlled under the Austrian 
Act on new psychoactive substances (Neue-Psychoaktive-
Substanzen-Gesetz, NPSG).
QQ In Poland, MDMB-CHMICA is controlled according to the 
general definition of ‘substitute drug’ which has been 
included to the Act of 8 October 2010 amending the Act on 
counteracting drug addiction and the Act on State Sanitary 
Inspection (Journal of Laws ‘Dz.U.’ No. 213, item 1396). 
Article 44b of the above mentioned Act bans manufacturing 
or introducing substitute drugs to trade.
One Member State (Sweden) and Norway reported that 
MDMB-CHMICA is controlled under other types of legislation:
(28) Systematic name: 1- methoxy-3-[4- β –methoxyphenethyl)-piperazin-1-yl]-1-
phenylpropan-2-ol
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QQ In Sweden, MDMB-CHMICA is controlled Act on the 
Prohibition of Certain Goods Dangerous to Health (SFS 
1999:42).
QQ In Norway, the import of and trade in MDMB-CHMICA is 
controlled by Medicinal Products Legislation. 
Fourteen Member States (Belgium, Bulgaria, Czech Republic 
(29), France, Hungary, Italy, Ireland, Malta, Portugal, Romania, 
Slovakia, Slovenia, Spain, and the United Kingdom) reported 
that MDMB-CHMICA is not subject to control measures at the 
national level.
I 3.8.  Further information (Article 5.2(h) of the Council Decision)
3.8.1.  The chemical precursors that are known to have 
been used for the manufacture of the substance
No information was reported by the Member States, Turkey, or 
Norway, about the chemical precursors or manufacturing 
methods used to make the MDMB-CHMICA which has been 
detected within Europe. 
The synthesis of MDMB-CHMICA may be carried out in 
analogy to the synthesis of the indazole analogue MDMB-
CHMINACA, which has been described previously in a patent 
application (Buchler et al., 2011; Buchler et al., 2009). It is also 
possible that MDMB-CHMICA can be synthesised using 
synthesis routes for similar compounds as described by 
Banister and colleagues (Banister et al., 2015) and by Adam 
and colleagues (Adam et al., 2010).
Possible synthetic routes for the production of MDMB-
CHMICA could utilise L-tert-leucine methyl ester (for the 
synthesis of the (S) enantiomer), indole-3-carboxylic acid, 
indole-3-carboxylic acid methyl ester, indole and 
cyclohexylmethyl bromide, as potential precursors.
3.8.2.  The mode and scope of the established or 
expected use of the new substance
No studies were identified that have examined the mode and 
scope of established or expected use of MDMB-CHMICA. 
Given the limited information currently available, the relevant 
information has been included in the previous sections.
(29) The Czech Republic reported that an amendment of the Government 
Regulation No. 463/2013 Coll., on the lists of addictive substances is 
currently being prepared. MDMB-CHMICA is one of the 33 substances 
proposed to place under control.
3.8.3.  Other use of the new psychoactive substance 
and the extent of such use, the risks associated 
with this use of the new psychoactive substance, 
including the health and social risks
No information was provided by any Member State that 
indicated that MDMB-CHMICA had any other use apart from 
in analytical reference materials and scientific research.
From the available information, it does not appear that 
MDMB-CHMICA is used in the manufacture of a medicinal 
product in the European Union. However, the data collection is 
incomplete and some countries indicated that this information 
is not known. It is understood that the collection of such 
information is a challenge in the absence of a European Union 
database on the synthetic route of all medicinal products.
In addition, the EMA reported that it is not known if MDMB-
CHMICA is used in the manufacture of medicinal products for 
human or veterinary use and which are centrally authorised 
within the European Union.
I 4.  Information from the EMA (Article 5.3 of the Council Decision)
I 4.1. Marketing authorization
Twenty two countries (Austria, Belgium, Croatia, Czech 
Republic, Denmark, Estonia, Finland, Germany, Greece, 
Hungary, Iceland, Ireland, Latvia, Malta, Norway, Poland, 
Portugal, Slovakia, Slovenia, Spain, Sweden, and the United 
Kingdom) reported that MDMB-CHMICA has not been granted 
a marketing authorization as a medicinal product for human 
use. Twenty five countries (Austria, Belgium, Croatia, Czech 
Republic, Denmark, Estonia, Finland, France, Germany, 
Greece, Hungary, Iceland, Ireland, Italy, Latvia, Netherlands, 
Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, 
Sweden, and the United Kingdom) reported that MDMB-
CHMICA has not been granted a marketing authorization as a 
medicinal product for veterinary use.
The EMA also reported that MDMB-CHMICA has not been 
granted a marketing authorization as a medicinal product for 
neither human nor veterinary use through the centralized 
procedure.
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I 4.2. Application for a marketing authorization
Twenty two countries (Austria, Belgium, Croatia, Czech 
Republic, Denmark, Estonia, Finland, Germany, Greece, 
Hungary, Iceland, Ireland, Latvia, Malta, Norway, Poland, 
Portugal, Slovakia, Slovenia, Spain, Sweden, and the United 
Kingdom) reported that MDMB-CHMICA is not the subject of 
an application for a marketing authorization as a medicinal 
product for human use. 
Twenty five countries (Austria, Belgium, Croatia, Czech 
Republic, Denmark, Estonia, Finland, France, Germany, 
Greece, Hungary, Iceland, Ireland, Italy, Latvia, Netherlands, 
Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, 
Sweden, and the United Kingdom) reported that MDMB-
CHMICA is not the subject of an application for a marketing 
authorization as a medicinal product for veterinary use.
The EMA also reported that MDMB-CHMICA is not the subject 
of an application for a marketing authorization for neither 
human nor veterinary use through the centralized procedure.
I 4.3. Suspended marketing authorization
Twenty two countries (Austria, Belgium, Croatia, Czech 
Republic, Denmark, Estonia, Finland, Germany, Greece, 
Hungary, Iceland, Ireland, Latvia, Malta, Norway, Poland, 
Portugal, Slovakia, Slovenia, Spain, Sweden, and the United 
Kingdom) reported that that there had been no cases of 
suspended marketing authorization granted in respect to 
MDMB-CHMICA as a human medicine. 
Twenty five countries (Austria, Belgium, Croatia, Czech 
Republic, Denmark, Estonia, Finland, France, Germany, 
Greece, Hungary, Iceland, Ireland, Italy, Latvia, Netherlands, 
Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, 
Sweden, and the United Kingdom) reported that that there had 
been no cases of suspended marketing authorization granted 
in respect to MDMB-CHMICA as a veterinary medicine. 
The EMA also reported that MDMB-CHMICA is not the subject 
of a suspended marketing authorization for neither human nor 
veterinary use through the centralized procedure.
I 5. Conclusion
MDMB-CHMICA is a highly potent full agonist at the CB
1
 
receptor of the endocannabinoid system. While it shares some 
pharmacological similarities with Δ9-tetrahydrocannabinol 
(THC), which is responsible for the major psychoactive effects 
of cannabis, laboratory studies suggest that it is much more 
potent. Overall, very little is known about the pharmacology of 
MDMB-CHMICA, including its effects on other physiological 
systems.
MDMB-CHMICA has been available on the European drug 
market since at least 2014. It has been detected in 19 Member 
States, Turkey, and Norway. More than 3 600 seizures have 
been made, which includes 43 kg of powder and 54 kg of 
herbal material which has been laced with MDMB-CHMICA. 
This herbal material is typically sold as branded ‘legal high’ 
smoking mixtures in head shops as well as on the Internet; the 
products are marketed as ‘legal’ replacements to cannabis. 
Due to the way that these products are produced, it appears 
that users are at risk of serious poisoning.
Information reported to Europol and the EMCDDA suggests 
that bulk powders of MBMB-CHMICA are imported from 
chemical companies based in China. These powders are then 
used to produce smoking mixtures within Europe. A large 
number of products have been detected on the market. Of 
note is that MDMB-CHMICA was controlled in China in 
October 2015 which might reduce the availability of bulk 
powders in Europe. 
To date, 71 serious adverse events associated with MDMB-
CHMICA have been reported by 8 Member States. This 
includes serious acute intoxications requiring hospitalisation 
and 29 deaths; in at least 12 cases MDMB-CHMICA appeared 
to play a role in the death.
We conclude that the health and social risks caused by the 
manufacture, trafficking and use of MDMB-CHMICA, and the 
involvement of organised crime and possible consequences of 
control measures, could be thoroughly assessed through a 
risk assessment procedure in accordance with Article 6 of 
Council Decision 2005/387/JHA. 
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